NervGen Pharma adds material change to F-10

NervGen Pharma Corp. submitted a Form 6-K as a foreign private issuer for January 2026.

Accepted by SEC EDGAR 01/08/2026 - 04:09 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

NervGen Pharma Corp. submitted a Form 6-K as a foreign private issuer for January 2026. The company confirms it files annual reports under Form 40-F, which is the standard for certain Canadian issuers.

Exhibit 99.1, a Material Change Report dated January 8, 2026, is included with this submission and is incorporated by reference into NervGen’s Form F-10 registration statement (File No. 333-292197). The report is signed on behalf of the company by Chief Financial Officer William J. Adams.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NervGen Pharma Corp. (NGENF) file in this Form 6-K?

NervGen Pharma filed a Form 6-K as a foreign private issuer, including a Material Change Report as Exhibit 99.1. The filing updates U.S. investors and links this report to its existing Form F-10 registration statement.

How does this Form 6-K affect NervGen Pharma (NGENF)'s registration?

The Form 6-K incorporates Exhibit 99.1, a Material Change Report, into NervGen’s Form F-10 registration statement. This means the material change disclosure becomes part of the information available for registered securities in the United States.

Which annual report form does NervGen Pharma (NGENF) use with the SEC?

NervGen Pharma indicates it files its annual reports under Form 40-F. This is commonly used by certain Canadian issuers that report under Canada’s disclosure regime but access U.S. markets under a multijurisdictional disclosure system.

What document is attached as Exhibit 99.1 to NervGen (NGENF)'s Form 6-K?

Exhibit 99.1 is a Material Change Report dated January 8, 2026. This document, although not detailed here, presumably describes a specific material corporate event and is formally added to the company’s Form F-10 registration statement.

Who signed NervGen Pharma (NGENF)'s January 2026 Form 6-K?

The Form 6-K was signed on behalf of NervGen Pharma by William J. Adams, the company’s Chief Financial Officer. His signature confirms the company’s authorization of the submission under the Securities Exchange Act of 1934.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File Number: 001-43048

NERVGEN PHARMA CORP.
(Exact name of Registrant as specified in its charter)

N/A
(Translation of Registrant’s name)

112-970 Burrard Street, Unit 1290
Vancouver, British Columbia, Canada V6Z 2R4
Telephone: (778) 731-1711
(Address and telephone number of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ¨            Form  40-F x

INCORPORATION BY REFERENCE

Exhibit 99.1 of this Form 6-K is incorporated by reference into the registrant’s Registration Statement on Form F-10 (File No. 333-292197).

DOCUMENTS INCLUDED AS PART OF THIS REPORT

Exhibit
99.1		Material Change Report, dated January 8, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NERVGEN PHARMA CORP.
Date: January 8, 2026	By:	/s/ William J. Adams
		Name: William J. Adams
		Title: Chief Financial Officer